ArticleJournal, genetic engineering & biotechnology2026
Combating Streptococcus agalactiae infections by designing a multi-epitope vaccine using molecular dynamic simulations.
Article in Journal, genetic engineering & biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo construct a multi-epitope vaccine using virulent proteins of Streptococcus agalactiae strain 2603 V/R.
backgroundStreptococcus agalactiae strain 2603 V/R is causative agent of various diseases and infections in neonates, pregnant women as well as elderly patients with significant underlying diseases. World health organisation reported high number of new born deaths and stillbirths. Various studies have shown that no licensed vaccine is available against meningitis caused by GBS. Therefore, new preventive methods against GBS are desirable to be developed.
objectives1. To identify antigenic proteins from proteome of Streptococcus agalactiae 2603 V/R. 2. Identification of epitopes from filtered-out proteins. 3. Designing a multi-epitope vaccine using epitopes of screened proteins and validating it with docking analysis and simulation studies.
methodsThe proteins of pathogen Streptococcus agalactiae strain 2603 V/R were analysed to obtain antigenic proteins which were further used for B and T cell epitope predictions using various reverse vaccinology-based tools. Finally, by applying immunoinformatics approach a MEV construct was designed. Molecular docking analysis was performed for better understanding of binding energy and further validation was done using molecular dynamic simulations.
results4 target proteins were screened for construction of MEV using 27 predicted epitopes and docking analysis demonstrated vaccine interaction with TLR, MHC I and MHC II having binding energy -40.862 kcal/mol, -43.866 kcal/mol and -56.942 kcal/mol. Simulation studies demonstrated that the vaccine complexed with immune and MHC receptors was stable during the simulation time.
conclusionsThe isolated virulent proteins provided insights into crucial targets for development of an efficient, highly specific, and safe MEV construct. The anticipated vaccine construct will potentially provide a long-term immunity to majority of people against Streptococcus agalactiae.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.